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Abstract
Background: B cell immunity, including the chemokine CXCL13, has an established role in Lyme neuroborreliosis,
and also, T helper (Th) 17 immunity, including IL-17A, has recently been implicated.
Methods: We analysed a set of cytokines and chemokines associated with B cell and Th17 immunity in cerebrospinal
fluid and serum from clinically well-characterized patients with definite Lyme neuroborreliosis (group 1, n = 49),
defined by both cerebrospinal fluid pleocytosis and Borrelia-specific antibodies in cerebrospinal fluid and from
two groups with possible Lyme neuroborreliosis, showing either pleocytosis (group 2, n = 14) or Borrelia-specific
antibodies in cerebrospinal fluid (group 3, n = 14). A non-Lyme neuroborreliosis reference group consisted of 88
patients lacking pleocytosis and Borrelia-specific antibodies in serum and cerebrospinal fluid.
Results: Cerebrospinal fluid levels of B cell-associated markers (CXCL13, APRIL and BAFF) were significantly elevated in
groups 1, 2 and 3 compared with the reference group, except for BAFF, which was not elevated in group 3. Regarding
Th17-associated markers (IL-17A, CXCL1 and CCL20), CCL20 in cerebrospinal fluid was significantly elevated in groups 1,
2 and 3 compared with the reference group, while IL-17A and CXCL1 were elevated in group 1. Patients with
time of recovery <3 months had lower cerebrospinal fluid levels of IL-17A, APRIL and BAFF compared to patients
with recovery >3 months.
Conclusions: By using a set of markers in addition to CXCL13 and IL-17A, we confirm that B cell- and Th17-associated
immune responses are involved in Lyme neuroborreliosis pathogenesis with different patterns in subgroups.
Furthermore, IL-17A, APRIL and BAFF may be associated with time to recovery after treatment.
Keywords: Lyme neuroborreliosis, Cerebrospinal fluid, Cytokines, Chemokines, APRIL, BAFF, CCL20, CXCL 1,
CXCL13, IL-17A
Background
Lyme neuroborreliosis (LNB) is the dominating dissemi-
nated form of Lyme borreliosis in Sweden [1] as well as
in Europe [2]. The pathogenesis of LNB involves a com-
plex immune response with an initial innate response
elicited by Borrelia burgdorferi (B.b.) interacting with
recognition receptors such as Toll-like receptor 2, subse-
quently resulting in activation and recruitment of B and
T cells to the central nervous system (CNS). The chemo-
kine C-X-C motif ligand (CXCL)13 is a key molecule in
B cell recruitment to the CNS [3], and several studies
have shown high concentrations of CXCL13 in the cere-
brospinal fluid (CSF) in both children and adults with
LNB [4–6]. CXCL13 is postulated to be a diagnostic
marker in acute LNB since it may be elevated in CSF
before intrathecally produced B.b.-specific antibodies
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can be detected; however, different cutoff levels have been
discussed, e.g. 142 and 250 pg/mL, respectively [4–8]. The
cytokines a proliferation-inducing ligand (APRIL) and B
cell activating factor (BAFF) are important in B cell de-
velopment and survival [9], and raised CSF levels have
been detected in other neuroinflammatory conditions
[10, 11]. Although increased BAFF levels in CSF have
been reported in LNB [12], the relative contribution of
B cell-associated factors such as CXCL13, APRIL and
BAFF in LNB inflammation and clinical outcome is
mainly unknown.
Recent studies have indicated involvement of T helper
(Th)17 cells in the intrathecal immune response in
patients with LNB [13–15]. IL-17A, a cytokine produced
by Th17 cells, is a potent activator of neutrophils in
defeating extracellular microbes, but its wider role in
the pathogenesis and clinical outcome of LNB is un-
clear [13, 16, 17]. CXCL1 (previously known as growth
regulated oncogene-α, GRO-α), a neutrophil recruiting
chemokine, and CCL20 (macrophage inflammatory
protein-3α, MIP-3α) a Th17 recruiting chemokine, are
both induced by Th17 cells [17]. While elevated IL-17A
levels in CSF have been reported in LNB [13–15], infor-
mation on its potential association with clinical out-
come is still lacking, and it is not known if chemokines
downstream of Th17 are increased in LNB.
A basic understanding of the molecules involved in
the pathogenesis is a prerequisite for the identification
of prognostic biomarkers and in the long run for finding
potential therapeutic targets. The aims of this study were
to evaluate the putative involvement of Th17- and B
cell-associated immune response and to assess associa-
tions with disease course in LNB by analysing IL-17A and
its downstream chemokines CCL20 and CXCL1, as well
as B cell-associated factors APRIL, BAFF and CXCL13.
Methods
Patients
We included retrospectively 165 patients in Jönköping
County, Sweden, who had been investigated by lumbar
puncture (LP) and blood sampling during 2007–2009 to
verify or exclude suspected LNB. Medical records were
scrutinized, and the patients were divided into four
groups based on the CSF findings (see Tables 1, 2 and 3
for demographic and clinical characteristics) and in ac-
cordance with the European Federation of Neurological
Societies (EFNS) guidelines [18]. Patients in group 1
(definite LNB, n = 49) had both CSF pleocytosis and
Borrelia-specific antibodies in CSF. Group 2 (possible
LNB pleocytosis, n = 14) had symptoms strongly sug-
gestive of LNB, short duration of symptoms and CSF
pleocytosis but not (yet) Borrelia-specific antibodies in
CSF. Group 3 (possible LNB Ab+, n = 14) had Borrelia-
specific antibodies in CSF, but no pleocytosis and
symptoms were less suggestive of LNB. As a non-LNB
reference group, we selected 88 gender- and age-
matched patients from the same cohort investigated for
suspected LNB 2007–2009, in whom LNB was excluded
based on no Borrelia-specific serum or CSF antibodies, no
CSF pleocytosis and normal CSF-albumin. The reference
group consisted of patients where the LP was part of a
neurological investigation and in whom no neurological
diagnosis was verified (n = 56) or they later received other
neurological diagnoses such as Bell’s palsy (n = 18) or
Alzheimer’s disease, Parkinson’s disease and stroke (n = 14).
Serum and CSF
Serum and CSF samples were drawn prior to antibiotic
treatment and stored at −20 °C.
All tests were performed at the clinical laboratory of
microbiology in Jönköping. Borrelia-specific antibodies
in serum and CSF were analysed using Lyme Borreliosis
ELISA kit 2nd generation (Dako Cytomation, A/S,
Glostrup, Denmark) between 2007 and 2008. Intrathecal
antibody index (AI) was calculated using total IgG as a
reference molecule [19] according to the formula:
((Borrelia-specific IgG in CSF (OD)/Borrelia-specific
IgG in serum (OD))/((total IgG in CSF (mg/L)/total
IgG in serum (g/L)) [20]. A Borrelia-specific AI >2 was
indicative of intrathecal anti-Borrelia antibody produc-
tion. From 2009, the laboratory used the IDEIA (Lyme
Neuroborreliosis kit, (Dako Cytomation)). Both anti-
body assays use purified, native B. afzelii strain DK1
flagellum as test antigen, and results were interpreted
according to the manufacturer’s instructions.
Cytokine and chemokine analyses
APRIL, BAFF and CXCL13 were analysed by ELISA (Invi-
trogen Immunoassay Kit, KHC3051, Life Technologies,
USA, and Quantikine, DBLYSOB and DCX130, (R&D)
Systems, Inc., USA, respectively). IL-17A, CXCL1 and
CCL20 were analysed by Luminex multiple bead tech-
nology (Milliplex Human Cytokine/Chemokine Kit,
Millipore Corporation, Germany). All analyses were
conducted according to the manufacturers’ instruc-
tions. The lowest detection limits were as follows:
APRIL: 0.02 pg/mL, BAFF: 0.05 pg/mL in serum,
0.04 pg/mL in CSF; CXCL13: 0.04 pg/mL in serum,
0.03 pg/mL in CSF; IL-17A: 0.38 pg/mL in serum,
0.06 pg/mL in CSF; CXCL1: 3.2 pg/mL in serum,
0.14 pg/mL in CSF; CCL20: 0.29 pg/mL in serum,
0.84 pg/mL in CSF. Values under the detection limit
were given half the value of the lowest point of the
standard curve.
Data handling and statistical analyses
For statistical analyses, SPSS version 20 was used. Inter-
group comparisons were performed by using the non-
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parametrical Kruskal-Wallis test and when p < 0.05
followed by Mann-Whitney U test as a post hoc test. For
children (age < 15 years), a covariance analysis has been
performed with pleocytosis as a covariate. Data are given
as medians and interquartile (i.q. range). For categorical
variables, the chi-square test was used. Correlations were
determined by Spearman’s rank order correlation. p values
below 0.05 were considered significant.
Results
General description of the patients
Table 1 presents the characteristics of the different study
groups. There were significant differences in age with,
older individuals in group 3 compared to group 2 which
consisted mainly of children. Median duration of symp-
toms before LP was similar in groups 1 and 3 but several
days shorter in group 2. A majority of patients in groups













Borrelia-specific AI or Borrelia-specific antibodies in CSF + – + –
CSF pleocytosis + + – –
Borrelia-specific IgG/IgM antibodies detected in serum, n (%) 43 (88) 11 (79) 8 (57) 0 (0)
CSF-albumin/S-albumin median (range) 16 (3.4–69)*** 5.8 (2.7–45)* 5.7 (2.4–17) 4.0 (1.5–9.5)
IgG-index median (range) 0.7 (0.0–2.6)*** 0.6 (0.4–0.8)*** 0.5 (0.4–0.6) 0.5 (0.0–0.6)
Men n (%) 29 (59) 9 (64) 8 (57) 39 (44)
Women n (%) 20 (41) 5 (36) 6 (43) 49 (56)
Median age years (range) 32 (4–72) 8.5 (3–39)** 62 (32–82)* 23 (1–83)
Median duration symptoms before LP weeks (range) 2.0 (0.1–104) 0.5 (0.1–3.0)* 2.0 (0.1–156) 4.0 (0.1–520)
Head/neck pain n (%) 32 (65) 6 (43) 8 (57) 27 (31)
Cranial nerve palsy n (%) 22 (45) 9 (64) 0 (0) 20 (23)
Radiculitis n (%) 20 (41) 2 (14) 1 (7) 0 (0)
Patients with duration of symptoms after treatment
under 3 months n (%)
40 (87)a 8 (57) 6 (67)b –
Pleocytosis: >5 mononuclear cells/mL CSF
LNB Lyme neuroborreliosis, n number of patients, Ab+ antibody, AI antibody index, CSF cerebrospinal fluid, S serum, LP lumbar puncture
*Significant difference compared to the non-LNB group (group 4). *p < 0.01, **p < 0.001, ***p < 0.0001
aGroup 1: information was lacking in 3 patients, thus total n = 46
bGroup 3: five patients did not receive any treatment, thus total n = 9
Table 2 Characteristics of clinical parameters in group 2 (possible LNB pleocytosis)




3 1.6 x x




8 0.1 x x x
9 0.4 x
10 0.3 x x
11 3.0 x x
12 0.7 x x x
13 1.0 x x x x
14 0.3 x x
LNB Lyme neuroborreliosis, Pat. Nr. patient number, LP lumbar puncture
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1 and 2 had symptom duration after treatment below
3 months. Tables 2 and 3 present symptoms and symp-
tom duration before LP for patients in groups 2 and 3,
respectively. All patients in group 2 had symptoms
highly suggestive of LNB such as head or neck pain (or
both), radiculitis or cranial nerve palsy. In group 3, no
patients had cranial nerve palsy and only one had radi-
culitis and six patients had symptoms not typical for
LNB, such as vision loss and dysarthria, and their
duration of symptoms before LP ranged from less than a
week to several years.
B cell-associated cytokines and chemokines
CSF levels of APRIL and CXCL13 (Table 4 and Fig. 1)
were significantly elevated in all LNB groups compared
to the non-LNB group (group 4) while there were no
differences in serum. A majority of patients in groups 1
and 2, but not in group 3, had CSF levels of CXCL13
Table 3 Characteristics of clinical parameters in group 3 (possible LNB Ab+)
Pat. Nr. Symptoms before LP Head/neck Fatigue Fever Vertigo Radiculitis Cranial nerve Other symptoms
Weeks Pain Palsy
1 72 x x
2 3 x x
3 156 Unilateral vision loss
4 2 x x
5 104 Dysarthria, dysphagia
6 52 Dysarthria, memory loss
7 7 x
8 1 x x
9 2 x x
10 0.7 Unilateral vision loss
11 0.4 x x Dysarthria, vision loss
12 0.1 x Decreased consciousness
13 2 x x
14 1 x Concentration difficulties
LNB Lyme neuroborreliosis, Pat. Nr. patient number, LP lumbar puncture
















S-APRIL (ng/mL) 3.1 (0.8–5.7) 1.4 (0.3–1.8) 2.0 (0.5–4.4) 3.9 (0.0–5.8)
S-BAFF (pg/mL) 705 (471–857) 586 (531–873) 597 (496–763) 730 (581–935)
S-CXCL13 (pg/mL) 67 (38–99) 56 (39–84) 41 (30–58) 54 (34–81)
S-IL-17A (pg/mL) 4.0 (2.6–10) 4.5 (2.9–9.2) 5.6 (2.9–7.1) 9.8 (2.6–24)
S-CXCL1 (pg/mL) 741 (549–861)*** 695 (598–1055) 599 (439–750)*** 1113 (830–2425)
S-CCL20 (pg(mL) 6.1 (3.7–9.3)*** 6.8 (5.3–13)*** 5.2 (3.1–9.8) 0.2 (0.2–8.2)
CSF-APRIL (ng/mL) 7.4 (4.7–17)*** 7.0 (4.6–9.7)*** 4.9 (3.9–6.1)*** 0.0 (0.0–2.9)
CSF-BAFF (pg/mL) 113 (58–191)*** 125 (81–203)*** 0.0 (0.0–76) 0.0 (0.0–25)
CSF-CXCL13 (pg/mL) 974 (738–2394)*** 379 (57–770)*** 3.4 (0.0–8.8)*** 0.0 (0.0–0.0)
CSF-IL-17A (pg/mL) 0.6 (0.0–0.6)*** 0.0 (0.0–0.2) 0.0 (0.0–0.1) 0.0 (0.0–0.0)
CSF-CXCL1 (pg/mL) 52 (16–117)*** 16 (2.1–37) 12 (4.4–21)* 21 (16–26)
CSF-CCL20 (pg/mL) 2.5 (2.2–2.8)*** 2.3 (1.9–2.6)*** 2.2 (1.9–2.5)*** 0.4 (0.4–0.4)
Pleocytosis: >5 mononuclear cells/mL CSF
CSF cerebrospinal fluid, LNB Lyme neuroborreliosis, n number of patients, Ab+ antibody, S serum
*Significant difference compared to the non-LNB group (group 4). *p < 0.01, ***p < 0.0001
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Fig. 1 B cell- and Th17-related cytokine/chemokine levels in cerebrospinal fluid (CSF).Group 1: definite Lyme neuroborreliosis (LNB), patients with
Borrelia-specific antibodies in CSF and pleocytosis. Group 2: possible LNB pleocytosis, patients with CSF pleocytosis but no detectable Borrelia-specific
antibodies in CSF. Group 3: possible LNB Ab+, patients with Borrelia-specific antibodies in CSF but no pleocytosis. Group 4: non-LNB, patients without
CSF pleocytosis and no detectable Borrelia-specific antibodies in serum or CSF. Bars represent the median cytokine/chemokine level in each group
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over the previously suggested cutoff levels of 142 and
250 pg/mL (Table 5). No correlations were seen between
cytokine and chemokine levels in serum and CSF.
Th17-associated cytokines and chemokines
CSF levels of IL-17A, CXCL1 and CCL20 (Table 4 and
Fig. 1), were all significantly elevated in group 1 com-
pared to group 4. CCL20 was also significantly higher in
groups 2 and 3 compared to group 4. In Table 4, serum
levels of CXCL1 were significantly lower in groups 1 and
3 compared to group 4 whereas levels of CCL20 were
significantly higher in groups 1 and 2 compared to
group 4. CSF levels of IL-17A correlated with CXCL1
(rho = 0.72, p < 0.0001) in groups 1, 2 and 3. No correla-
tions were seen between cytokine and chemokine levels
in serum and CSF.
Associations with demographic and clinical parameters
There were no significant differences in cytokine/chemo-
kine levels in serum or in CSF between men and
women. Regarding differences in relation to age (data
not shown), we found that children <15 years of age in
groups 1, 2 and 3 (n = 34) had significantly higher levels
of BAFF (median 108 pg/mL, i.q. range 60–165, p < 0.001)
in serum and CXCL13 in serum and CSF (77 pg/mL,
47–109, p = 0.001 and 920 pg/mL, 398–1706, p = 0.03,
respectively) compared to adults. BAFF in serum also
showed a strong negative correlation with age in groups
1 and 2 (rho = −0.57, p < 0.01). APRIL, BAFF and
CXCL13 in CSF were all positively correlated with pleo-
cytosis (rho = 0.51, rho = 0.51 and rho = 0.55, respectively,
all p < 0.001). When a covariate analysis was performed
with pleocytosis as a covariate, BAFF in serum was still
significantly higher in children (p < 0.0001), but CXCL13
in serum and CSF was not. Children in groups 1, 2 and 3
had significantly higher levels of CCL20 in serum and CSF
(8 pg/mL, 4–12 and median 3 pg/mL, 2–3, respectively,
both p = 0.03). CCL20 was however not significantly
higher when performing a covariate analysis with pleocy-
tosis as a covariate. IL-17A levels in CSF correlated with
pleocytosis (rho = 0.51, p < 0.0001).
Symptom duration before LP did not correlate with
levels of cytokines/chemokines in serum or CSF in
groups 1, 2 and 3 together. However, within group 2,
duration of symptoms before LP correlated negatively
with BAFF and CXCL13 in serum (rho = −0.57 and
−0.58, respectively, both p < 0.01). When stratifying pa-
tient in groups 1, 2 and 3 according to duration of symp-
toms before LP, those with a shorter duration (<2 weeks,
n = 49) had higher levels of BAFF in serum (median
764 ng/mL, 537–890, p = 0.002) compared to patients with
longer symptom duration (n = 28) (556 ng/mL, 438–668).
Regarding relation to disease course, patients in groups
1 and 2 were stratified according to time to recovery after
treatment. Patients with shorter duration, group A
(<3 months, n = 54) had lower levels of APRIL (p = 0.003),
BAFF (p = 0.04) and IL-17A (p = 0.02) in CSF compared to
patients with longer time of recovery, group B (>3 months,
n = 6), (Fig. 2).
Discussion
In this study, we showed that levels of several cytokines
and chemokines related to Th17 and B cell immunity
are raised in CSF from patients with LNB, strengthening
the involvement of both Th17 and B cell immunity in
LNB. Furthermore, we noted several relations to demo-
graphic and clinical parameters.
The lack of correlations between cytokine/chemokine
levels in serum versus CSF indicates an intrathecal
source of the cytokines and chemokines present in CSF,
thus reflecting the pathological process in the CNS.
B cell-related cytokines and chemokines
CXCL13 was significantly elevated in CSF of all LNB
groups, in particular the pleocytosis groups 1 and 2, as
compared to the non-LNB group. CXCL13 has been
suggested as a diagnostic marker for acute LNB, and a
majority of patients in groups 1 and 2, those with most
probable acute LNB, showed raised CSF levels above 142
and 250 pg/mL, respectively, while no patients in group 3
had levels over 142 pg/mL, supporting CXCL13 as a diag-
nostic tool and corroborating several studies [4, 6–8, 21].
Patients in groups 1 and 2 with CSF CXCL13 levels below
the cutoff values did not, however, differ in symptoms,
duration of symptoms before LP or time to recovery after
treatment compared to patients with higher levels of
CXCL13. Other diagnoses than LNB cannot be completely
ruled out in patients with CSF-CXCL13 levels below
142 pg/mL, especially in group 2, since this group only
displayed CSF pleocytosis. We suggest that the LNB diag-
nosis in group 3 is questionable since these patients
displayed no CSF pleocytosis and had CSF-CXCL13
levels below the suggested cutoff 142 pg/mL. Most of
these patients reported symptoms less typical for LNB.
Thus, the elevated AI could more likely reflect a previous
infection, and other causes of their present symptoms are
plausible. However, interestingly, slightly higher APRIL
Table 5 Number of patients with CXCL13 levels in CSF over 142

















>142 pg/mL n (%) 43 (88) 10 (71) 0 (0) 1 (1)
>250 pg/mL n (%) 42 (86) 9 (64) 0 (0) 0 (0)
Pleocytosis: >5 mononuclear cells/mL CSF
CSF cerebrospinal fluid, LNB Lyme neuroborreliosis, n number of patients,
Ab+ antibody
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and CXCL13 CSF levels were found in this group com-
pared with the non-LNB group, which may indicate a
subtle ongoing B cell-related activity. On the other
hand, CSF levels of CXCL1 were lower, strengthening
group 3 as a different entity. Finally, regarding age, we
corroborated previous findings [6] of increased levels of
CXCL13 in children in both serum and CSF.
The involvement of B cell-related cytokines and che-
mokines in the pathogenesis of LNB is also supported by
the raised CSF levels of both APRIL and BAFF in groups
1 and 2, the groups with most probable LNB. This is, to
our knowledge, the first time elevated levels of APRIL
has been reported in LNB patients, while BAFF has been
studied previously [12]. The raised levels of APRIL and
BAFF support the critical role of B cell activation and
proliferation in LNB. However, moderately increased
CSF levels of these cytokines were associated with
shorter time to recovery (defined as <3 months), while
higher levels were found in patients with longer time to
recovery. Speculatively, moderate levels reflect an appro-
priate B cell response, while higher levels may reflect an
over-shooting response mirroring or even contributing
to more extensive CNS pathology. Increased levels of
APRIL and BAFF have also been found in patients with
multiple sclerosis [22] and systemic lupus erythematosus
[11, 23], linked to antibody-mediated pathology and
neuropsychiatric symptoms, respectively. Clearly, the
role of APRIL and BAFF in LNB needs to be further elu-
cidated, preferably in a prospective manner.
Th17-related cytokines and chemokines
We found elevated CSF levels of IL-17A in LNB patients,
which corroborates previous studies [13–15]. We here
extended the concept of Th17 immunity by showing
elevated levels of CXCL1 and CCL20, both induced by
Th17 and involved in recruitment of neutrophils and
Th17 cells, respectively. CXCL1 in CSF, was significantly
raised in group 1, while CCL20 in CSF was significantly
raised in all definite and possible LNB (groups 1, 2 and 3).
This is, to our knowledge, the first study that shows these
Th17-related markers in patients with LNB. IL-17A,
CXCL1 and CCL20 have however been reported present
in other Lyme borreliosis manifestations, such as Lyme
arthritis (IL-17), erythema migrans and acrodermatitis
chronica atrophicans (CXCL1 and CCL20) [24, 25]. In
experimental studies, CXCL1 was shown to be produced
by human astrocytes and brain microvascular endothelial
cells in response to B. burgdorferi [26]. Interestingly, pa-
tients who recovered within 3 months after treatment had
lower levels of IL-17A in CSF. Thus, high levels of IL-17A
in CSF may be a prognostic marker and speculatively, a
Th17 response could be involved in the pathogenesis of a
delayed therapeutic response. In line with this notion, pa-
tients with prolonged symptoms after treatment of neuro-
syphilis had higher levels of IL-17A in CSF [27]. Further
on, Th17 immunity has been linked to many autoimmune
conditions, like rheumatoid arthritis [28] and psoriasis
[29]. In CNS, Th17-related immune responses play a role
Fig. 2 APRIL, BAFF and IL-17A levels in cerebrospinal fluid (CSF) in
relation to duration of symptoms after treatment in group 1 (definite
Lyme neuroborreliosis) and group 2 (possible Lyme neuroborreliosis
with CSF pleocytosis) taken together. Group A: patients with time of
recovery after treatment <3 months. Group B: patients with time of
recovery after treatment >3 months. Bars represent the median cytokine
level in each group
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in experimental autoimmune encephalomyelitis (EAE), an
animal model for multiple sclerosis [30]. CCL20 can bind
to the choroid plexus and lead Th17-related cells into
CNS [30]. Our findings add further aspects of the Th17-
related immune response in the pathogenesis of LNB and
suggest that it may affect clinical course, although this
needs to be confirmed.
There are some limitations of the current study. The
retrospective design hampers clinical assessments. Another
potential limitation is the lack of truly healthy controls,
although the chosen group represents a clinically rele-
vant reference group. Group 2, with mostly children,
had CSF pleocytosis and characteristic symptoms of
LNB, but other, foremost viral, infections cannot be
completely ruled out, especially in cases with low CSF
levels of CXCL13, since presence of neurotropic viruses
was mostly not investigated. Regarding the EFNS guide-
lines, we note some limitations in the classification of
possible LNB cases. According to the guidelines, patients
corresponding to our groups 2 and 3 are classified as pos-
sible LNB, while we find important differences between
the two groups in terms of clinical presentation and CSF
findings, including cytokine and chemokine levels.
Conclusions
We here demonstrate additional support for Th17
involvement in the intrathecal immune response in LNB
as well as indications that high levels of IL-17A in CSF
in the acute phase of the disease may be associated with
slower recovery, hence proposing that IL-17A should be
further evaluated as a possible biomarker for prognosis.
Besides CXCL13, the B cell-related cytokines APRIL and
BAFF are elevated in CSF from patients with LNB, and
the levels could be associated with time to recovery after
treatment.
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